Back to Search
Start Over
Assessment of Swallowing Function in Patients with Head and Neck Squamous Cell Carcinoma in High vs. Low Dose Cisplatin.
- Source :
-
Cancer Investigation . December 2023, Vol. 41 Issue 10, p807-815. 9p. - Publication Year :
- 2023
-
Abstract
- Cisplatin-based therapies are standard-of-care for advanced-stage head and neck squamous cell carcinoma (HNSCC). Treatment regimens include 3 weeks of high-dose bolus cisplatin or 6–7 weeks of low-dose weekly cisplatin, both with concurrent radiation. The effects of cisplatin dosage on swallowing function warrant further study. A 237-patient cohort treated for HNSCC at a single center were studied retrospectively. Gastrostomy tube dependence served as the primary endpoint. Secondary endpoints included weight changes, esophageal stricture, and lymphedema. The primary/secondary outcomes were not statistically significant; however, ototoxicity and renal toxicity were significantly higher in the high-dose group. These findings add insight into cisplatin dose-based functional outcomes. [ABSTRACT FROM AUTHOR]
- Subjects :
- *NEPHROTOXICOLOGY
*THERAPEUTIC use of antineoplastic agents
*LYMPHEDEMA
*DEGLUTITION
*BODY weight
*HEAD & neck cancer
*RETROSPECTIVE studies
*COMPARATIVE studies
*FEEDING tubes
*CISPLATIN
*OTOTOXICITY
*DESCRIPTIVE statistics
*COMBINED modality therapy
*ESOPHAGEAL stenosis
*SQUAMOUS cell carcinoma
*LONGITUDINAL method
*DISEASE risk factors
RISK factors
Subjects
Details
- Language :
- English
- ISSN :
- 07357907
- Volume :
- 41
- Issue :
- 10
- Database :
- Academic Search Index
- Journal :
- Cancer Investigation
- Publication Type :
- Academic Journal
- Accession number :
- 174558663
- Full Text :
- https://doi.org/10.1080/07357907.2023.2283452